Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 31;9(3):e1128.
doi: 10.7759/cureus.1128.

Effect of Referral Patterns and Treatment Type on Oncologic Outcomes for Women with Ductal Carcinoma In Situ

Elaine S Wai  1 , Mary Lesperance  2 , Linghong Lu  2 , Cheryl S Alexander  3 , Pauline T Truong  1
Affiliations

Effect of Referral Patterns and Treatment Type on Oncologic Outcomes for Women with Ductal Carcinoma In Situ

Elaine S Wai et al. Cureus. .

Abstract

Objective: Management of ductal carcinoma in situ (DCIS) remains controversial. This study examined long-term outcomes in a population-based cohort of patients with pure DCIS treated with breast-conserving surgery (BCS) alone, BCS + radiotherapy (RT), and mastectomy. Outcomes were compared between patients referred versus not referred for oncologic assessment after definitive surgery.

Materials and methods: Subjects were 2575 women diagnosed between 1985 and 1999. Data from several electronic databases were linked and analyzed. Outcomes were invasive local recurrence-free survival (ILRFS), mastectomy-free survival (MFS), breast cancer-specific survival (BCSS), and overall survival (OS).

Results: Median follow-up time was 9.8 years. Overall, 56% (n = 1448) of subjects were referred to a cancer centre. Factors associated with non-referral were older age, comorbidities, and travel distance. Ten-year MFS, BCSS, and OS were higher among referred patients (all p ≤ 0.001). In cohorts treated with BCS alone (n = 1314) vs. BCS + RT (n = 510) vs. mastectomy (n = 751), 10-year ILRFS were 93.7% vs. 96.6% vs. 97.7%, (p < 0.001) and BCSS were 97.6% vs. 99.8% vs. 98.6%, (p = 0.01). Corresponding rates of ipsilateral invasive breast relapse at 10 years were 6.3% after BCS alone, 3.4% after BCS + RT, and 2.3% after mastectomy (p < 0.001). On multivariable analysis, factors associated with improved ILRFS were older age at diagnosis, low comorbidity score, absence of comedo histology, mastectomy, and post-BCS RT.

Conclusion: Patients with DCIS referred for oncologic assessment were more likely to undergo post-BCS RT, resulting in lower mastectomy and higher survival rates compared to non-referred patients. Patients with significant comorbidities were less likely to be referred and experienced lower ILRFS and BCSS. Referral for multidisciplinary oncologic assessment after surgery is warranted to individualize management and optimize outcomes for patients with DCIS.

Keywords: breast cancer; breast conservation; ductal carcinoma in situ; local recurrence; mastectomy; outcomes; prognostic factors; radiation therapy; referral.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Comparisons of Kaplan-Meier. (A) Invasive local recurrence-free survival and (B) breast cancer-specific survival by referral status.
Figure 2
Figure 2. Comparisons of Kaplan-Meier. (A) Invasive local recurrence-free survival and (B) breast cancer-specific survival by treatment type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Saving normal tissues - a goal for the ages.
    Groves AM, Williams JP. Groves AM, et al. Int J Radiat Biol. 2019 Jul;95(7):920-935. doi: 10.1080/09553002.2019.1589654. Epub 2019 Mar 29. Int J Radiat Biol. 2019. PMID: 30822213 Free PMC article. Review.

References

    1. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Ernster VL, Barclay J, Kerlikowske K, et al. Arch Intern Med. 2000;160:953–958. - PubMed
    1. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Goodwin A, Parker S, Ghersi D, et al. Cochrane Database Syst Rev. 2013;11:0. - PMC - PubMed
    1. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, et al. J Natl Cancer Inst Monogr. 2010;2010:162–177. - PMC - PubMed
    1. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. Solin LJ, Gray R, Hughes LL, et al. J Clin Oncol. 2015;33:3938–3944. - PMC - PubMed
    1. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. Wong JS, Kaelin CM, Troyan SL, et al. J Clin Oncol. 2006;24:1031–1036. - PubMed

LinkOut - more resources